Crinetics Pharmaceuticals Finds $40M

San Diego-based Crinetics Pharmaceuticals, a company developing treatments for endocrine disorders, said this morning that it has raised $40M in a Series A funding. The funding was led by 5AM Ventures, Versant Ventures, and Vivo Capital. As part of the funding, Wendell Wierenga has been named as its Chairman, and 5AM's Mason Freeman, , Versant's Steve Kaldor, and Vivo Capital's Mahendra Shah have all joined the board. Crinetics said it is developing a small molecule somatostatin agonist for the treatment of acromegaly, a hormonal disorder caused by over-secretion of growth hormone. More information »